Sale

Multiple Sclerosis Treatment Market

Global Multiple Sclerosis Treatment Market Share, Size, Trends, Growth, Forecast: By Indication Type: Clinically Isolated Syndrome (CIS), Relapse-remitting MS (RRMS), Primary Progressive MS (PPMS), Secondary Progressive MS (SPMS); By Diagnosis Method; By Treatment Method; By End Users; Regional Analysis; Supplier Landscape; 2024-2032

Global Multiple Sclerosis Treatment Market Outlook

The global multiple sclerosis treatment market size is driven by the rising prevalence of multiple sclerosis. The market attained a value of USD 27.44 billion in 2023. The market is further expected to grow at a CAGR of 4.3% during the forecast period of 2024-2032 to attain a value of USD 40.08 billion by 2032.

 

multiple sclerosis treatment market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Multiple Sclerosis Insights: Types, Causes, Symptoms, and Diagnosis

Multiple sclerosis is an autoimmune disorder in which the body’s immune system begins to attack its healthy cells. In this disorder, the cells of the myelin sheath surrounding the brain and the spinal cord are damaged by the immune system leading to impaired nerve signals from the brain to the other organs of the body.             

 

Depending on the onset and the severity, there are four types of multiple sclerosis, that are clinically isolated syndrome, relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis.

 

The exact cause of this disease is still unclear and is under research, however, it is set to be triggered by the associated bacterial or viral infections, certain kinds of genetic mutations or some environmental factors.

 

Optic neuritis or other vision problems is the first noticeable symptom of multiple sclerosis. Muscle spasms, irregular coordination, muscle weakness, numbness, fatigue, and changes in gait are some of the common symptoms of this disorder.

 

The early and accurate diagnosis of multiple sclerosis is difficult as the symptoms of this disease are like other neurological disorders. However, blood tests, imaging tests and MRI scans are the exploratory tests used to diagnose multiple sclerosis. The confirmatory tests evoked potential tests and spinal taps are further done to ensure the prevalence of multiple sclerosis.

 

Multiple sclerosis is more prevalent in women as compared to men due to the differences in the immune system, lifestyle, and other genetic factors.

 

The multiple sclerosis treatment market can be categorised into the following segments:

 

multiple sclerosis treatment market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Indication Type

  • Clinically Isolated Syndrome (CIS)
  • Relapse-remitting MS (RRMS)
  • Primary Progressive MS (PPMS)
  • Secondary Progressive MS (SPMS)

 

Market Breakup by Diagnosis Method

  • Blood and Imaging Tests
  • Spinal Tap (Lumbar Puncture)
  • Magnetic Resonance Imaging
  • Evoked Potential Tests
  • Others

 

Market Breakup by Treatment Method

  • Corticosteroids
  • Plasma Exchange (Plasmapheresis)
  • Injectable Treatments
    • Interferon Beta Medications
    • Glatiramer Acetate (Glatopa)
  • Oral Treatments
    • Fingolimod (Gilenya)
    • Dimethyl fumarate (Tecfidera)
    • Siponimod (Mayzent)
  • Infusion Treatments
    • Ocrelizumab (Ocrevus)
    • Natalizumab (Tysabri)
    • Alemtuzumab (Campath, Lemtrada)

 

Market Breakup by End Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

multiple sclerosis treatment market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Scenario

The growth of the multiple sclerosis treatment market is driven by the rising prevalence and incidence of multiple sclerosis disease. By 2030, nearly 5 million subjects are expected to suffer from different types of multiple sclerosis.

 

The market is further driven by the rising focus of the key players on discovering novel products. For example, many key companies such as Biogen, Novartis, Bristol Myers Squibb Company, and many more are developing new drugs for the treatment of multiple sclerosis.

 

Besides, the heavy investments by the key players in the research and developmental activities are also expected to benefit the market. Big pharmaceutical companies aim to target as many multiple sclerosis indications as possible to attract a wide array of customers.

 

North America to Account for the Largest Share

North America is anticipated to hold the largest share of the multiple sclerosis treatment market during the forecast period owing to the increasing demand for the multiple sclerosis therapeutics, advanced healthcare infrastructure, rising awareness and favourable government policies for the treatment.

 

Furthermore, the presence of the significant key players, Pfizer, Bayer, Novartis, and the higher prevalence of multiple sclerosis in this region, has attributed to the growth of the North American market during the forecast period.

 

Therapeutic Landscape

There is no approved treatment regimen for the management of multiple sclerosis. However, the progression of the disease is controlled by the adoption of multiple treatment strategies.

 

Different Therapeutic Interventions in the Multiple Sclerosis Treatment Market

Firstly, healthcare professionals aim for the treatment of the symptoms. The symptomatic therapies target muscle spasticity, ataxia, pain, impaired movements, and bladder control.

 

The management of acute exacerbations is generally treated with the incorporation of Intravenous Immunoglobin, Corticosteroids, and plasma exchange or Plasmapheresis. Corticosteroids such as Prednisolone are most used for reducing nerve inflammation. In case of steroids failure, Plasmapheresis is wedded to manage the moderate to severe symptoms.

 

The major area of research and innovation spins around the treatment with disease-altering therapies. These treatment strategies can minimise the relapse frequencies and slow down the accumulation of physical disability. At present, there are approximately twelve disease-altering therapies approved for the management of the relapsing types of multiple sclerosis. These therapeutic interventions can be delivered orally, subcutaneously, and intravenously.

 

Ocrelizumab is one of the approved disease-modifying intravenous infusions used for treating primary progressive and relapse-remitting multiple sclerosis. Interferon beta medications are a set of injectable treatments to provide immediate multiple sclerosis symptomatic relief. The oral treatments for multiple sclerosis include Fingolimod, Teriflunomide and Dimethyl Fumarate.

 

Other medications, such as muscle relaxants and physical therapies, also assist in the alleviation of the symptoms of multiple sclerosis.

 

Clinical Trials Landscape

There is the availability of few disease-modifying therapies, henceforth there is the need for clinical trials for the discovery of novel therapeutic agents. Clinical studies are essential to assess the safety, efficacy, tolerability, and pharmacokinetics of pipeline products.

 

Emerging Therapies Aiding the Multiple Sclerosis Treatment Market Growth

A novel drug, ADS-5102, a formulation of amantadine, is under clinical studies. The drug has been found beneficial in the treatment of impaired movements in progressive multiple sclerosis. 

 

The Food and Drug Administration has recently approved a new oral drug, Ponvory, for the management of multiple sclerosis. During the clinical trials, the drug has reduced brain lesions and relapses by 30 per cent, hence being found effective in treating multiple sclerosis.

 

Emerging therapies such as BTK (Bruton’s Tyrosine Kinase) inhibitors are under evaluation for analysing their therapeutic effect and adverse effects. This acts by modulating B cells in the central nervous system.

 

Stem cell transplantation is another potent therapy found effective in the management of this disease. In this therapy, the destroyed immune system of multiple sclerosis patients is replaced by healthy stem cells. This therapy is still under investigation, and once approved can create plausible therapeutic prospects.

 

The ongoing research and developmental activities have shown promising benefits and opportunities and are anticipated to fuel the market growth during the forecast period.

 

Competitive Landscape

The report gives an in-depth analysis of the key players involved in the multiple sclerosis treatment market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Opexa Therapeutics, Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • Actelion Pharmaceuticals Ltd.
  • GSK plc
  • Novartis AG
  • Johnson & Johnson
  • AstraZeneca plc
  • Merck KGaA
  • Abbott Laboratories

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Indication Type
  • Diagnosis Method
  • Treatment Method
  • End Users
  • Region
Breakup by Indication Type
  • Clinically Isolated Syndrome (CIS)
  • Relapse-remitting MS (RRMS)
  • Primary Progressive MS (PPMS)
  • Secondary Progressive MS (SPMS)
Breakup by Diagnosis Method
  • Blood and Imaging Tests
  • Spinal Tap (Lumbar Puncture)
  • Magnetic Resonance Imaging
  • Evoked Potential Tests
  • Others
Breakup by Treatment Method
  • Corticosteroids
  • Plasma Exchange (Plasmapheresis)
  • Injectable Treatments
  • Oral Treatments
  • Infusion Treatments
Breakup by End Users
  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives & Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Opexa Therapeutics, Inc.
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A.
  • GSK plc
  • Novartis AG
  • Johnson & Johnson
  • AstraZeneca plc
  • Merck KGaA
  • Abbott Laboratories

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
2    Research Methodology
3    Executive Summary
4    Multiple Sclerosis Overview

    4.1    Guidelines and Stages
    4.2    Pathophysiology
    4.3    Screening and Diagnosis
    4.4    Treatment Pathway 
5    Patient Profile
    5.1    Patient Profile Overview
    5.2    Patient Psychology and Emotional Impact Factors
    5.3    Risk Assessment and Treatment Success Rate
6    Current Scenario Evaluation and Regulatory Framework
    6.1    Emerging Therapies and Clinical Trials
    6.2    Patent Landscape 
        6.2.1    Patent Overview
            6.2.1.1    Patent Status and Expiry
            6.2.1.2    Timelines from Drug Development to Commercial Launch
            6.2.1.3    New Drug Application
                6.2.1.3.1    Documentation and Approval Process
    6.3    Cost of Treatment
    6.4    Regulatory Framework
        6.4.1    Regulatory Overview
            6.4.1.1    US FDA
            6.4.1.2    EU EMA
            6.4.1.3    INDIA CDSCO
            6.4.1.4    JAPAN PMDA
            6.4.1.5    Others
7    Challenges and Unmet Needs
    7.1    Treatment Pathway Challenges
    7.2    Compliance and Drop-Out Analysis
    7.3    Awareness and Prevention Gaps
8    Global Multiple Sclerosis Treatment Market
    8.1    Global Multiple Sclerosis Treatment Market Overview
    8.2    Global Multiple Sclerosis Treatment Market Analysis 
        8.2.1    Market Overview
            8.2.1.1    Global Multiple Sclerosis Treatment Market Historical Value (2017-2023) 
            8.2.1.2    Global Multiple Sclerosis Treatment Market Forecast Value (2024-2032)
        8.2.2    Global Multiple Sclerosis Treatment Market by Indication Type
            8.2.2.1    Market Overview
                8.2.2.1.1    Clinically Isolated Syndrome (CIS) 
                8.2.2.1.2    Relapse-remitting MS (RRMS) 
                8.2.2.1.3    Primary Progressive MS (PPMS) 
                8.2.2.1.4    Secondary Progressive MS (SPMS)
        8.2.3    Global Multiple Sclerosis Treatment Market by Diagnosis Method 
            8.2.3.1    Market Overview
                8.2.3.1.1    Blood and Imaging Tests
                8.2.3.1.2    Spinal Tap (Lumbar Puncture)
                8.2.3.1.3    Magnetic Resonance Imaging
                8.2.3.1.4    Evoked Potential Tests
                8.2.3.1.5    Others
        8.2.4    Global Multiple Sclerosis Treatment Market by Treatment Method
            8.2.4.1    Market Overview
                8.2.4.1.1    Corticosteroids
                8.2.4.1.2    Plasma Exchange (Plasmapheresis)
                8.2.4.1.3    Injectable Treatments
                    8.2.4.1.3.1    Interferon Beta Medications
                    8.2.4.1.3.2    Glatiramer Acetate (Glatopa)
                8.2.4.1.4    Oral Treatments
                    8.2.4.1.4.1    Fingolimod (Gilenya)
                    8.2.4.1.4.2    Dimethyl fumarate (Tecfidera)
                    8.2.4.1.4.3    Siponimod (Mayzent)
                8.2.4.1.5    Infusion Treatments
                    8.2.4.1.5.1    Ocrelizumab (Ocrevus)
                    8.2.4.1.5.2    Natalizumab (Tysabri)
                    8.2.4.1.5.3    Alemtuzumab (Campath, Lemtrada)
        8.2.5    Global Multiple Sclerosis Treatment Market by End Users
            8.2.5.1    Market Overview
                8.2.5.1.1    Hospitals
                8.2.5.1.2    Specialty Clinics
                8.2.5.1.3    Homecare
                8.2.5.1.4    Others
        8.2.6    Global Multiple Sclerosis Treatment Market by Region
            8.2.6.1    Market Overview
                8.2.6.1.1    North America
                8.2.6.1.2    Europe
                8.2.6.1.3    Asia Pacific
                8.2.6.1.4    Middle East and Africa
                8.2.6.1.5    Latin America
                8.2.6.1.6    Others
9    North America  Multiple Sclerosis Treatment Market
    9.1    Market Share by Country
    9.2    United States of America
        9.2.1    Historical Trend (2017-2023)
        9.2.2    Forecast Trend (2024-2032)
    9.3    Canada
        9.3.1    Historical Trend (2017-2023)
        9.3.2    Forecast Trend (2024-2032)
10    Europe Multiple Sclerosis Treatment Market
    10.1    Market Share by Country
    10.2    United Kingdom
        10.2.1    Historical Trend (2017-2023)
        10.2.2    Forecast Trend (2024-2032)
    10.3    Germany
        10.3.1    Historical Trend (2017-2023)
        10.3.2    Forecast Trend (2024-2032)
    10.4    France
        10.4.1    Historical Trend (2017-2023)
        10.4.2    Forecast Trend (2024-2032)
    10.5    Italy
        10.5.1    Historical Trend (2017-2023)
        10.5.2    Forecast Trend (2024-2032)
    10.6    Others
11    Asia Pacific Multiple Sclerosis Treatment Market
    11.1    Market Share by Country
    11.2    China
        11.2.1    Historical Trend (2017-2023)
        11.2.2    Forecast Trend (2024-2032)
    11.3    Japan
        11.3.1    Historical Trend (2017-2023)
        11.3.2    Forecast Trend (2024-2032)
    11.4    India
        11.4.1    Historical Trend (2017-2023)
        11.4.2    Forecast Trend (2024-2032)
    11.5    ASEAN
        11.5.1    Historical Trend (2017-2023)
        11.5.2    Forecast Trend (2024-2032)
    11.6    Australia
        11.6.1    Historical Trend (2017-2023)
        11.6.2    Forecast Trend (2024-2032)
    11.7    Others
12    Latin America Multiple Sclerosis Treatment Market
    12.1    Market Share by Country
    12.2    Brazil
        12.2.1    Historical Trend (2017-2023)
        12.2.2    Forecast Trend (2024-2032)
    12.3    Argentina
        12.3.1    Historical Trend (2017-2023)
        12.3.2    Forecast Trend (2024-2032)
    12.4    Mexico
        12.4.1    Historical Trend (2017-2023)
        12.4.2    Forecast Trend (2024-2032)
    12.5    Others
13    Middle East and Africa Multiple Sclerosis Treatment Market
    13.1    Market Share by Country
    13.2    Saudi Arabia
        13.2.1    Historical Trend (2017-2023)
        13.2.2    Forecast Trend (2024-2032)
    13.3    United Arab Emirates
        13.3.1    Historical Trend (2017-2023)
        13.3.2    Forecast Trend (2024-2032)
    13.4    Nigeria
        13.4.1    Historical Trend (2017-2023)
        13.4.2    Forecast Trend (2024-2032)
    13.5    South Africa
        13.5.1    Historical Trend (2017-2023)
        13.5.2    Forecast Trend (2024-2032)
    13.6    Others
14    Global Multiple Sclerosis Treatment Market Dynamics
    14.1    Market Drivers and Constraints
    14.2    SWOT Analysis
    14.3    Porter’s Five Forces Model 
    14.4    Key Demand Indicators 
    14.5    Key Price Indicators 
    14.6    Industry Events, Initiatives & Trends 
    14.7    Value Chain Analysis
15    Supplier Landscape
    15.1    Opexa Therapeutics, Inc.
        15.1.1    Company Overview
        15.1.2    Product Portfolio
        15.1.3    Demographic Reach and Achievements
        15.1.4    Mergers and Acquisitions
        15.1.5    Certifications
    15.2    Bayer AG
        15.2.1    Company Overview
        15.2.2    Product Portfolio
        15.2.3    Demographic Reach and Achievements
        15.2.4    Mergers and Acquisitions
        15.2.5    Certifications
    15.3    Teva Pharmaceutical Industries Ltd.
        15.3.1    Company Overview
        15.3.2    Product Portfolio
        15.3.3    Demographic Reach and Achievements
        15.3.4    Mergers and Acquisitions
        15.3.5    Certifications
    15.4    Sanofi S.A.
        15.4.1    Company Overview
        15.4.2    Product Portfolio
        15.4.3    Demographic Reach and Achievements
        15.4.4    Mergers and Acquisitions
        15.4.5    Certifications
    15.5    GSK plc
        15.5.1    Company Overview
        15.5.2    Product Portfolio
        15.5.3    Demographic Reach and Achievements
        15.5.4    Mergers and Acquisitions
        15.5.5    Certifications
    15.6    Novartis AG
        15.6.1    Company Overview
        15.6.2    Product Portfolio
        15.6.3    Demographic Reach and Achievements
        15.6.4    Mergers and Acquisitions
        15.6.5    Certifications
    15.7    Johnson & Johnson
        15.7.1    Company Overview
        15.7.2    Product Portfolio
        15.7.3    Demographic Reach and Achievements
        15.7.4    Mergers and Acquisitions
        15.7.5    Certifications
    15.8    AstraZeneca plc
        15.8.1    Company Overview
        15.8.2    Product Portfolio
        15.8.3    Demographic Reach and Achievements
        15.8.4    Mergers and Acquisitions
        15.8.5    Certifications
    15.9    Merck KGaA
        15.9.1    Company Overview
        15.9.2    Product Portfolio
        15.9.3    Demographic Reach and Achievements
        15.9.4    Mergers and Acquisitions
        15.9.5    Certifications
    15.10    Abbott Laboratories
        15.10.1    Company Overview
        15.10.2    Product Portfolio
        15.10.3    Demographic Reach and Achievements
        15.10.4    Mergers and Acquisitions
        15.10.5    Certifications
16    Multiple Sclerosis Treatment Market- Drug Distribution Model (Additional Insight)
    16.1    Overview 
    16.2    Potential Distributors 
    16.3    Key Parameters for Distribution Partner Assessment
17    Payment Methods (Additional Insight)
    17.1    Government Funded
    17.2    Private Insurance
    17.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market is primarily driven by the rising cases of multiple sclerosis, increasing research and developmental activities and novel product launches and approvals.

Based on the indication type, the multiple sclerosis treatment market is categorized into Clinically Isolated Syndrome (CIS), Relapse-remitting MS (RRMS), Primary Progressive MS (PPMS), and Secondary Progressive MS (SPMS).

Based on the diagnosis method, the market is segmented into blood and imaging tests, spinal tap (lumbar puncture), MRI (Magnetic Resonance Imaging), and evoked potential tests, among others.

Based on the treatment method, the market is bifurcated into corticosteroids, plasma exchange (plasmapheresis), oral treatments, infusion treatments, and injectable treatments.

Based on the end users, the market is divided into hospitals, speciality clinics, and home care, among others.

The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. North America is anticipated to hold a significant share of the market during the forecast period.

The key companies involved in the market are Opexa Therapeutics, Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., GSK plc, Novartis AG, Johnson & Johnson, AstraZeneca plc, Merck KGaA, and Abbott Laboratories, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER